Remibrutinib (Blinded) + Remibrutinib (Open Label)
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Myasthenia Gravis
Conditions
Generalized Myasthenia Gravis
Trial Timeline
Feb 7, 2025 → Feb 26, 2033
NCT ID
NCT06744920About Remibrutinib (Blinded) + Remibrutinib (Open Label)
Remibrutinib (Blinded) + Remibrutinib (Open Label) is a phase 3 stage product being developed by Novartis for Generalized Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06744920. Target conditions include Generalized Myasthenia Gravis.
What happened to similar drugs?
12 of 20 similar drugs in Generalized Myasthenia Gravis were approved
Approved (12) Terminated (3) Active (7)
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06744920 | Phase 3 | Recruiting |
Competing Products
20 competing products in Generalized Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 35 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 29 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |